Completed PHASE3 INTERVENTIONAL 4-arm NCT01001234

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)

A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents

Sponsor: Organon and Co

Conditions Migraine, Acute

Interventions placebo rizatriptan

Updated 9 times since 2017 Last updated: Apr 17, 2024 Started: Nov 30, 2009 Primary completion: Apr 21, 2011 Completion: Apr 21, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01001234, this PHASE3 trial focuses on Migraine, Acute and remains completed. Sponsored by Organon and Co, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2024 — Jul 2024 [monthly]

Completed PHASE3
Mar 2022 — Jun 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jul 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Jul 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.